QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
NASDAQ:CBAY

CymaBay Therapeutics - CBAY Stock Forecast, Price & News

$8.26
+0.46 (+5.90%)
(As of 01/30/2023 02:53 PM ET)
Add
Compare
Today's Range
$7.78
$8.46
50-Day Range
$3.27
$8.06
52-Week Range
$1.67
$8.46
Volume
1.15 million shs
Average Volume
1.77 million shs
Market Capitalization
$699.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
56.3% Upside
$12.80 Price Target
Short Interest
Bearish
4.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.94mentions of CymaBay Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.22) to ($1.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

256th out of 1,049 stocks

Pharmaceutical Preparations Industry

123rd out of 514 stocks


CBAY stock logo

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Stock News Headlines

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Short Interest Update
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Cymabay Therapeutics Inc
CymaBay to Host Virtual Analyst Day Next Week
CymaBay Therapeutics Misses Q2 EPS by 2c
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Company Calendar

Last Earnings
11/14/2022
Today
1/30/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.80
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+55.0%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
4 Analysts

Profitability

Net Income
$-90,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.93 per share

Miscellaneous

Free Float
79,939,000
Market Cap
$699.47 million
Optionable
Optionable
Beta
0.19

Key Executives

  • Sujal Shah
    President, Chief Executive Officer & Director
  • Daniel Menold
    Vice President-Finance
  • Charles A. McWherter
    President-Research & Development
  • Dennis D. KimDennis D. Kim
    Chief Medical Officer
  • Paul T. Quinlan
    Secretary & Chief Compliance Officer













CBAY Stock - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12-month price targets for CymaBay Therapeutics' shares. Their CBAY share price forecasts range from $8.00 to $19.00. On average, they predict the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2023?

CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 24.4% and is now trading at $7.80.
View the best growth stocks for 2023 here
.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our CBAY earnings forecast
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $7.80.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $660.50 million. The biopharmaceutical company earns $-90,000,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 1/30/2023 by MarketBeat.com Staff